Geron (Nasdaq:GERN) - Aandelenkoers, Nieuws & Analyse

GERN Overzicht aandelen

Geron Corporation, een laat-stadium klinisch biofarmaceutisch bedrijf, richt zich op de ontwikkeling en commercialisering van therapeutica voor myeloïde hematologische maligniteiten. Meer informatie

GERN fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 89.2% onder onze schatting van de reële waarde

De winst zal naar verwachting met 72.41% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Geron Corporation Concurrenten

SpringWorks Therapeutics

NasdaqGS:SWTX

US$2.9b

Centessa Pharmaceuticals

NasdaqGS:CNTA

US$2.3b

Protagonist Therapeutics

NasdaqGM:PTGX

US$2.7b

Arcellx

NasdaqGS:ACLX

US$4.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Geron
Historische aandelenkoersen
Huidige aandelenkoers	US$4.06
52 Week Hoogtepunt	US$5.34
52 Week Laag	US$1.64
Bèta	0.51
11 maand verandering	0%
3 maanden verandering	-9.98%
1 Jaar Verandering	112.57%
33 jaar verandering	174.32%
5 jaar verandering	170.67%
Verandering sinds IPO	-47.61%

Recent nieuws en updates

Geron: A Post Earnings And Funding Announcement Assessment

Nov 07

Is Geron (NASDAQ:GERN) Using Too Much Debt?

Oct 28

Recent updates

Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

May 03

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Mar 15

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Mar 05

Is Geron (NASDAQ:GERN) A Risky Investment?

Aug 25

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

May 12

An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Dec 20

Geron: A Major Catalyst For Shareholders Arrives In January - At Last

Sep 16

Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?

Sep 14

Geron rises on narrower-than-expected Q2 loss

Aug 12

Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt

Aug 05

Geron: Waiting For Godot

Jul 15

Rendement voor aandeelhouders

	GERN	US Biotechs	US Markt
7D	7.1%	4.0%	2.0%
1Y	112.6%	18.0%	32.4%

Rendement versus industrie: GERN overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 18 % opleverde.

Rendement versus markt: GERN overtrof de US markt, die het afgelopen jaar een rendement opleverde van 32.4 %.

Prijsvolatiliteit

Is GERN's price volatile compared to industry and market?
GERN volatility
GERN Average Weekly Movement	6.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: GERN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van GERN is het afgelopen jaar gedaald van 16% naar 7%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1990	141	Chip Scarlett	www.geron.com

Geron Corporation, een laat-stadium klinisch biofarmaceutisch bedrijf, richt zich op de ontwikkeling en commercialisering van therapeutica voor myeloïde hematologische maligniteiten. Het bedrijf ontwikkelt imetelstat, een telomeraseremmer die zich in Fase 3 van het klinisch onderzoek bevindt en die de ongecontroleerde proliferatie van kwaadaardige stam- en progenitorcellen in myeloïde hematologische maligniteiten remt voor de behandeling van myelodysplastische syndromen met laag of intermediair-1 risico en myelofibrose met intermediair-2 of hoog risico. Het bedrijf werd opgericht in 1990 en het hoofdkantoor is gevestigd in Foster City, Californië.

Geron Corporation Samenvatting

Hoe verhouden de winst en inkomsten van Geron zich tot de beurswaarde?
GERN fundamentele statistieken
Marktkapitalisatie	US$2.48b
Inkomsten(TTM)	-US$201.19m
Inkomsten(TTM)	US$29.48m

83.3x

P/S-verhouding

-12.2x

Koers/Winstverhouding

Is GERN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GERN resultatenrekening (TTM)
Inkomsten	US$29.48m
Kosten van inkomsten	US$112.38m
Brutowinst	-US$82.90m
Overige uitgaven	US$118.29m
Inkomsten	-US$201.19m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.33
Brutomarge	-281.22%
Nettowinstmarge	-682.47%
Schuld/Eigen Vermogen Verhouding	28.7%

Hoe presteerde GERN op de lange termijn?

Bekijk historische prestaties en vergelijking

GERN Overzicht aandelen

Beloningen

Risicoanalyse

Geron Corporation Concurrenten

NasdaqGS:SWTX

US$2.9b

NasdaqGS:CNTA

US$2.3b

NasdaqGM:PTGX

US$2.7b

NasdaqGS:ACLX

US$4.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Consensus revenue estimates increase by 55%

Geron Corporation Appoints Joseph Eid as Executive Vice President, Research and Development

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron: A Post Earnings And Funding Announcement Assessment

Geron Corporation Announces New Data to Be Present at Upcoming ASH Annual Meeting Highlighting Potential of RYTELO (Imetelstat) in Myeloid Hematologic Malignancies

Is Geron (NASDAQ:GERN) Using Too Much Debt?

Recent updates

Consensus revenue estimates increase by 55%

Geron Corporation Appoints Joseph Eid as Executive Vice President, Research and Development

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron: A Post Earnings And Funding Announcement Assessment

Geron Corporation Announces New Data to Be Present at Upcoming ASH Annual Meeting Highlighting Potential of RYTELO (Imetelstat) in Myeloid Hematologic Malignancies

Is Geron (NASDAQ:GERN) Using Too Much Debt?

Geron Corporation to Report Q3, 2024 Results on Nov 07, 2024

Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition

Geron Corporation Announces Chief Commercial Officer to Depart, Effective August 31, 2024

Geron Corporation to Report Q2, 2024 Results on Aug 08, 2024

Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?

Executive VP & COO notifies of intention to sell stock

Chairman of the Board notifies of intention to sell stock

Geron: Innovative Rytelo Enters A Challenging MDS Market

Geron Corporation Announces FDA Approval of RYTELO (imetelstat) for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron Corporation to Report Q1, 2024 Results on May 02, 2024

Consensus revenue estimates decrease by 16%

Geron Corporation, Annual General Meeting, May 09, 2024

Geron Corporation has completed a Follow-on Equity Offering in the amount of $149.999995 million.

Price target increased by 7.0% to US$5.08

Consensus revenue estimates decrease by 13%

New major risk - Share price stability

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Geron Corporation Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Consensus revenue estimates decrease by 21%, EPS upgraded

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q4, 2023 Results on Feb 28, 2024

New minor risk - Share price stability

Forecast to breakeven in 2026

Geron Announces 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron Announces Publication in the Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Consensus revenue estimates increase by 76%

Geron Corporation has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Geron Corporation to Report Q3, 2023 Results on Nov 02, 2023

Geron Corporation Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Is Geron (NASDAQ:GERN) A Risky Investment?

Geron Corporation Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

Consensus revenue estimates fall by 14%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Geron Corporation to Report Q2, 2023 Results on Aug 03, 2023

Geron Corporation Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

Geron Corporation Announces Submission of New Drug Application to FDA for First-In-Class Telomerase Inhibitor Imetelstat

Geron Corporation Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

Geron Corporation Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Consensus revenue estimates increase by 29%

Geron Corporation Announces Board Changes

Consensus revenue estimates decrease by 48%, EPS upgraded

Geron Corporation Announces Five Abstracts Related to Imetelstat Accepts at European Hematology Association Annual Meeting

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q1, 2023 Results on May 11, 2023